LG Chem and Kyowa Kirin to Co-market Anemia Drug 'Nesp' and Hyperthyroidism Drug 'Regpara'

Korea Kyowa Kirin 'Nespr Prefilled Syringe Injection'

[Asia Economy Reporter Lee Chun-hee] LG Chem and Korea Kyowa Kirin announced on the 28th that they will jointly market the erythropoiesis-stimulating agent 'Nesp' for anemia in patients with chronic kidney disease (CKD) and the secondary hyperparathyroidism treatment 'Regpara' for CKD patients in South Korea.

'Nesp Prefilled Syringe (active ingredient: darbepoetin alfa)' is a long-acting erythropoiesis-stimulating agent used to treat anemia in patients with chronic kidney disease. It is prescribed for patients undergoing hemodialysis and peritoneal dialysis, as well as pre-dialysis CKD patients. It features high treatment convenience, requiring only a single administration every 1 to 2 weeks for dialysis patients. It was launched in South Korea in 2010.

'Regpara Tablets' (active ingredient: cinacalcet hydrochloride) is a once-daily oral medication approved by the U.S. Food and Drug Administration (FDA) in 2004 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Secondary hyperparathyroidism is a condition characterized by persistent overproduction of parathyroid hormone and enlargement of the parathyroid glands due to impaired kidney function. It is known as a progressive disease that worsens as chronic kidney disease advances.

Korea Kyowa Kirin 'Legpara Tablets'

Under this agreement, LG Chem will conduct sales activities at clinics and hospital-level institutions, while Korea Kyowa Kirin will focus on general hospitals. LG Chem plans to offer expanded treatment options to nephrology healthcare professionals by packaging these products with existing ones such as the first-generation erythropoiesis-stimulating agent 'Espogen' (active ingredient: erythropoietin) and the hyperkalemia treatment 'Nesticall' (active ingredient: calcium polystyrene sulfonate). They aim to present these enhanced options to medical professionals specializing in kidney diseases.

LG Chem stated, “We will continue to prioritize customer value by offering diverse treatment options. Based on our solid nationwide sales network and extensive experience in the nephrology field, we will do our best to expand the market quickly.” Korea Kyowa Kirin also said, “Through this joint sales partnership, we expect to increase awareness of 'Nesp' and 'Regpara' even in clinics and small to medium-sized hospitals. Both companies will strive to provide healthcare professionals with higher-quality information and ensure stable product supply.”

This content was produced with the assistance of AI translation services.